Experiment Number: 20306 - 03 Test Type: 90-DAY Route: GAVAGE Species/Strain: RATS/F 344/N	P10: STATIS	STICAL ANALYSIS OF NON-NEOPLASTIC LESIONS PCN 66/67 comparison study CAS Number: PCNCOMPARISN	Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT
		F1_Rev. 1_TCDD	
NTP Study Number:	C20306		
Lock Date:	10/07/2004		
Cage Range:	ALL		
Date Range:	ALL		
Reasons For Removal:	ALL		
Removal Date Range:	ALL		
Treatment Groups:	Include 001 0 NG/KG	Include 012 1 NG/KG	Include 013 10 NG/KG
	Include 014 50 NG/KG	Include 015 100 NG/KG	Include 016 200 NG/KG
Study Gender:	Female		
TDMSE Version:	3.0.2.2_002		
PWG Approval Date:	NONE		

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

PCN 66/67 comparison study CAS Number: PCNCOMPARISN

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF PCN 66/67 COMPARISON STUDY

FEMALE RATS

Organ Harderian Gland Kidney

Liver

Liver: Hepatocyte Pancreas Pancreas: Acinus Spleen Thymus Thyroid Gland

Morphology

Infiltration Cellular Mononuclear Cell Mineralization Nephropathy Hepatocyte, Multinucleate Inflammation Chronic Inflammation Granulomatous Pigmentation Toxic Hepatopathy Hypertrophy Infiltration Cellular Mononuclear Cell Atrophy Focal Hematopoietic Cell Proliferation Atrophy Cyst

PCN 66/67 comparison study CAS Number: PCNCOMPARISN Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Adrenal Cortex Infiltration Cellular Lympho	cyte					
LESION RATES						
OVERALL (a)	0/15 (0%)	1/10 (10%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/15.00	1/10.00	0/10.00	0/10.00	0/10.00	0/10.00
POLY-3 PERCENT (g)	0%	10%	0%	0%	0%	0%
TERMINAL (d)	0/15 (0%)	1/10 (10%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
FIRST INCIDENCE		94 (T)				
STATISTICAL TESTS						
POLY 3	P=0.474N	P=0.418	(e)	(e)	(e)	(e)
POLY 1.5	P=0.474N	P=0.418	(e)	(e)	(e)	(e)
POLY 6	P=0.474N	P=0.418	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.474N	P=0.400	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.433N	P=0.128	(e)	(e)	(e)	(e)

PCN 66/67 comparison study CAS Number: PCNCOMPARISN Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
drenal Cortex filtration Cellular Mononu	clear Cell					
LESION RATES						
OVERALL (a)	0/15 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	0/10 (0%)
POLY-3 RATE (b)	0/15.00	0/10.00	0/10.00	0/10.00	1/10.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	10%	0%
TERMINAL (d)	0/15 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	0/10 (0%)
FIRST INCIDENCE					94 (T)	
STATISTICAL TESTS						
POLY 3	P=0.531	(e)	(e)	(e)	P=0.418	(e)
POLY 1.5	P=0.531	(e)	(e)	(e)	P=0.418	(e)
POLY 6	P=0.531	(e)	(e)	(e)	P=0.418	(e)
COCH-ARM / FISHERS	P=0.531	(e)	(e)	(e)	P=0.400	(e)
MAX-ISO-POLY-3	P=0.339	(e)	(e)	(e)	P=0.128	(e)

PCN 66/67 comparison study CAS Number: PCNCOMPARISN Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Bone Marrow nflammation Histiocytic						
LESION RATES						
OVERALL (a)	0/15 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
POLY-3 RATE (b)	0/15.00	0/0.00	0/0.00	0/0.00	0/0.00	1/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	10%
TERMINAL (d)	0/15 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
FIRST INCIDENCE						94 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.418
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.418
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.418
COCH-ARM / FISHERS	P=0.233	(e)	(e)	(e)	(e)	P=0.400
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.128

PCN 66/67 comparison study CAS Number: PCNCOMPARISN Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Harderian Gland nfiltration Cellular Mononu	clear Cell					
LESION RATES						
OVERALL (a)	0/15 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/10 (20%)
POLY-3 RATE (b)	0/15.00	0/0.00	0/0.00	0/0.00	0/0.00	2/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	20%
TERMINAL (d)	0/15 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/10 (20%)
FIRST INCIDENCE						94 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.139
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.139
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.139
COCH-ARM / FISHERS	P=0.076	(e)	(e)	(e)	(e)	P=0.150
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.045*

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Heart Cardiomyopathy						
LESION RATES						
OVERALL (a)	9/15 (60%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	9/10 (90%)
POLY-3 RATE (b)	9/15.00	0/0.00	0/0.00	0/0.00	0/0.00	9/10.00
POLY-3 PERCENT (g)	60%	0%	0%	0%	0%	90%
TERMINAL (d)	9/15 (60%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	9/10 (90%)
FIRST INCIDENCE	94 (T)					94 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.115
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.115
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.115
COCH-ARM / FISHERS	P=0.079	(e)	(e)	(e)	(e)	P=0.118
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.064

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
ntestine Small, Jejunum nflammation Chronic						
LESION RATES						
OVERALL (a)	0/15 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
POLY-3 RATE (b)	0/15.00	0/0.00	0/0.00	0/0.00	0/0.00	1/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	10%
TERMINAL (d)	0/15 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
FIRST INCIDENCE						94 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.418
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.418
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.418
COCH-ARM / FISHERS	P=0.233	(e)	(e)	(e)	(e)	P=0.400
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.128

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Kidney Mineralization						
LESION RATES						
OVERALL (a)	15/15 (100%)	9/10 (90%)	9/10 (90%)	9/10 (90%)	8/10 (80%)	4/10 (40%)
POLY-3 RATE (b)	15/15.00	9/10.00	9/10.00	9/10.00	8/10.00	4/10.00
POLY-3 PERCENT (g)	100%	90%	90%	90%	80%	40%
TERMINAL (d)	15/15 (100%)	9/10 (90%)	9/10 (90%)	9/10 (90%)	8/10 (80%)	4/10 (40%)
FIRST INCIDENCE	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)
STATISTICAL TESTS						
POLY 3	P<0.001N**	P=0.418N	P=0.418N	P=0.418N	P=0.139N	P<0.001N**
POLY 1.5	P<0.001N**	P=0.418N	P=0.418N	P=0.418N	P=0.139N	P<0.001N**
POLY 6	P<0.001N**	P=0.418N	P=0.418N	P=0.418N	P=0.139N	P<0.001N**
COCH-ARM / FISHERS	P<0.001N**	P=0.400N	P=0.400N	P=0.400N	P=0.150N	P<0.001N**
MAX-ISO-POLY-3	P<0.001N**	P=0.128N	P=0.128N	P=0.128N	P=0.045N*	P<0.001N**

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Kidney Nephropathy						
LESION RATES						
OVERALL (a)	2/15 (13%)	1/10 (10%)	0/10 (0%)	2/10 (20%)	7/10 (70%)	3/10 (30%)
POLY-3 RATE (b)	2/15.00	1/10.00	0/10.00	2/10.00	7/10.00	3/10.00
POLY-3 PERCENT (g)	13.3%	10%	0%	20%	70%	30%
TERMINAL (d)	2/15 (13%)	1/10 (10%)	0/10 (0%)	2/10 (20%)	7/10 (70%)	3/10 (30%)
FIRST INCIDENCE	94 (T)	94 (T)		94 (T)	94 (T)	94 (T)
STATISTICAL TESTS						
POLY 3	P=0.008**	P=0.641N	P=0.328N	P=0.543	P=0.002**	P=0.309
POLY 1.5	P=0.008**	P=0.641N	P=0.328N	P=0.543	P=0.002**	P=0.309
POLY 6	P=0.008**	P=0.641N	P=0.328N	P=0.543	P=0.002**	P=0.309
COCH-ARM / FISHERS	P=0.016*	P=0.654N	P=0.350N	P=0.532	P=0.007**	P=0.301
MAX-ISO-POLY-3	P=0.013*	P=0.413N	P=0.137N	P=0.347	P<0.001**	P=0.180

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Kidney: Cortex Cyst						
LESION RATES						
OVERALL (a)	0/15 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	0/10 (0%)
POLY-3 RATE (b)	0/15.00	0/10.00	0/10.00	0/10.00	1/10.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	10%	0%
TERMINAL (d)	0/15 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	0/10 (0%)
FIRST INCIDENCE					94 (T)	
STATISTICAL TESTS						
POLY 3	P=0.531	(e)	(e)	(e)	P=0.418	(e)
POLY 1.5	P=0.531	(e)	(e)	(e)	P=0.418	(e)
POLY 6	P=0.531	(e)	(e)	(e)	P=0.418	(e)
COCH-ARM / FISHERS	P=0.531	(e)	(e)	(e)	P=0.400	(e)
MAX-ISO-POLY-3	P=0.339	(e)	(e)	(e)	P=0.128	(e)

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Liver Hepatocyte, Multinucleate						
LESION RATES						
OVERALL (a)	0/15 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	3/10 (30%)
POLY-3 RATE (b)	0/15.00	0/10.00	0/10.00	0/10.00	0/10.00	3/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	30%
TERMINAL (d)	0/15 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	3/10 (30%)
FIRST INCIDENCE						94 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	(e)	(e)	(e)	P=0.040*
POLY 1.5	P<0.001**	(e)	(e)	(e)	(e)	P=0.040*
POLY 6	P<0.001**	(e)	(e)	(e)	(e)	P=0.040*
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	(e)	(e)	P=0.052
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	P=0.013*

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Liver Hepatodiaphragmatic Nodul	e					
LESION RATES						
OVERALL (a)	1/15 (7%)	1/10 (10%)	1/10 (10%)	3/10 (30%)	2/10 (20%)	1/10 (10%)
POLY-3 RATE (b)	1/15.00	1/10.00	1/10.00	3/10.00	2/10.00	1/10.00
POLY-3 PERCENT (g)	6.7%	10%	10%	30%	20%	10%
TERMINAL (d)	1/15 (7%)	1/10 (10%)	1/10 (10%)	3/10 (30%)	2/10 (20%)	1/10 (10%)
FIRST INCIDENCE	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)
STATISTICAL TESTS						
POLY 3	P=0.478	P=0.668	P=0.668	P=0.156	P=0.356	P=0.668
POLY 1.5	P=0.478	P=0.668	P=0.668	P=0.156	P=0.356	P=0.668
POLY 6	P=0.478	P=0.668	P=0.668	P=0.156	P=0.356	P=0.668
COCH-ARM / FISHERS	P=0.477	P=0.650	P=0.650	P=0.159	P=0.346	P=0.650
MAX-ISO-POLY-3	P=0.369	P=0.395	P=0.395	P=0.075	P=0.184	P=0.395

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Liver Inflammation Chronic						
LESION RATES						
OVERALL (a)	7/15 (47%)	7/10 (70%)	8/10 (80%)	10/10 (100%)	9/10 (90%)	10/10 (100%)
POLY-3 RATE (b)	7/15.00	7/10.00	8/10.00	10/10.00	9/10.00	10/10.00
POLY-3 PERCENT (g)	46.7%	70%	80%	100%	90%	100%
TERMINAL (d)	7/15 (47%)	7/10 (70%)	8/10 (80%)	10/10 (100%)	9/10 (90%)	10/10 (100%)
FIRST INCIDENCE	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)
STATISTICAL TESTS						
POLY 3	P=0.002**	P=0.233	P=0.102	P=0.003**	P=0.028*	P=0.003**
POLY 1.5	P=0.002**	P=0.233	P=0.102	P=0.003**	P=0.028*	P=0.003**
POLY 6	P=0.002**	P=0.233	P=0.102	P=0.003**	P=0.028*	P=0.003**
COCH-ARM / FISHERS	P=0.005**	P=0.231	P=0.105	P=0.006**	P=0.034*	P=0.006**
MAX-ISO-POLY-3	P=0.002**	P=0.149	P=0.061	P=0.002**	P=0.015*	P=0.002**

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

	Females								
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG			
Liver Inflammation Granulomatou	IS								
LESION RATES									
OVERALL (a)	0/15 (0%)	0/10 (0%)	2/10 (20%)	0/10 (0%)	4/10 (40%)	4/10 (40%)			
POLY-3 RATE (b)	0/15.00	0/10.00	2/10.00	0/10.00	4/10.00	4/10.00			
POLY-3 PERCENT (g)	0%	0%	20%	0%	40%	40%			
TERMINAL (d)	0/15 (0%)	0/10 (0%)	2/10 (20%)	0/10 (0%)	4/10 (40%)	4/10 (40%)			
FIRST INCIDENCE			94 (T)		94 (T)	94 (T)			
STATISTICAL TESTS									
POLY 3	P<0.001**	(e)	P=0.139	(e)	P=0.008**	P=0.008**			
POLY 1.5	P<0.001**	(e)	P=0.139	(e)	P=0.008**	P=0.008**			
POLY 6	P<0.001**	(e)	P=0.139	(e)	P=0.008**	P=0.008**			
COCH-ARM / FISHERS	P<0.001**	(e)	P=0.150	(e)	P=0.017*	P=0.017*			
MAX-ISO-POLY-3	P<0.001**	(e)	P=0.045*	(e)	P=0.003**	P=0.003**			

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females	Females								
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG						
Liver												
Pigmentation												
LESION RATES												
OVERALL (a)	0/15 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	2/10 (20%)	4/10 (40%)						
POLY-3 RATE (b)	0/15.00	0/10.00	0/10.00	1/10.00	2/10.00	4/10.00						
POLY-3 PERCENT (g)	0%	0%	0%	10%	20%	40%						
TERMINAL (d)	0/15 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	2/10 (20%)	4/10 (40%)						
FIRST INCIDENCE				94 (T)	94 (T)	94 (T)						
STATISTICAL TESTS												
POLY 3	P<0.001**	(e)	(e)	P=0.418	P=0.139	P=0.008**						
POLY 1.5	P<0.001**	(e)	(e)	P=0.418	P=0.139	P=0.008**						
POLY 6	P<0.001**	(e)	(e)	P=0.418	P=0.139	P=0.008**						
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	P=0.400	P=0.150	P=0.017*						
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	P=0.128	P=0.045*	P=0.003**						

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Liver Toxic Hepatopathy						
LESION RATES						
OVERALL (a)	0/15 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)
POLY-3 RATE (b)	0/15.00	0/10.00	0/10.00	0/10.00	0/10.00	2/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	20%
TERMINAL (d)	0/15 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)
FIRST INCIDENCE						94 (T)
STATISTICAL TESTS						
POLY 3	P=0.005**	(e)	(e)	(e)	(e)	P=0.139
POLY 1.5	P=0.005**	(e)	(e)	(e)	(e)	P=0.139
POLY 6	P=0.005**	(e)	(e)	(e)	(e)	P=0.139
COCH-ARM / FISHERS	P=0.008**	(e)	(e)	(e)	(e)	P=0.150
MAX-ISO-POLY-3	P=0.006**	(e)	(e)	(e)	(e)	P=0.045*

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Liver: Hepatocyte Hypertrophy						
LESION RATES						
OVERALL (a)	1/15 (7%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	4/10 (40%)	8/10 (80%)
POLY-3 RATE (b)	1/15.00	0/10.00	0/10.00	0/10.00	4/10.00	8/10.00
POLY-3 PERCENT (g)	6.7%	0%	0%	0%	40%	80%
TERMINAL (d)	1/15 (7%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	4/10 (40%)	8/10 (80%)
FIRST INCIDENCE	94 (T)				94 (T)	94 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	P=0.580N	P=0.580N	P=0.580N	P=0.054	P<0.001**
POLY 1.5	P<0.001**	P=0.580N	P=0.580N	P=0.580N	P=0.054	P<0.001**
POLY 6	P<0.001**	P=0.580N	P=0.580N	P=0.580N	P=0.054	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.600N	P=0.600N	P=0.600N	P=0.064	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.229N	P=0.229N	P=0.229N	P=0.025*	P<0.001**

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Lung Inflammation Chronic						
LESION RATES						
OVERALL (a)	0/15 (0%)	0/10 (0%)	1/10 (10%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/15.00	0/10.00	1/10.00	0/10.00	0/10.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	10%	0%	0%	0%
TERMINAL (d)	0/15 (0%)	0/10 (0%)	1/10 (10%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
FIRST INCIDENCE			94 (T)			
STATISTICAL TESTS						
POLY 3	P=0.525N	(e)	P=0.418	(e)	(e)	(e)
POLY 1.5	P=0.525N	(e)	P=0.418	(e)	(e)	(e)
POLY 6	P=0.525N	(e)	P=0.418	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.525N	(e)	P=0.400	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.552N	(e)	P=0.128	(e)	(e)	(e)

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
ung 'igmentation Hemosiderin						
LESION RATES						
OVERALL (a)	0/15 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	0/10 (0%)
POLY-3 RATE (b)	0/15.00	0/10.00	0/10.00	0/10.00	1/10.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	10%	0%
TERMINAL (d)	0/15 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	0/10 (0%)
FIRST INCIDENCE					94 (T)	
STATISTICAL TESTS						
POLY 3	P=0.531	(e)	(e)	(e)	P=0.418	(e)
POLY 1.5	P=0.531	(e)	(e)	(e)	P=0.418	(e)
POLY 6	P=0.531	(e)	(e)	(e)	P=0.418	(e)
COCH-ARM / FISHERS	P=0.531	(e)	(e)	(e)	P=0.400	(e)
MAX-ISO-POLY-3	P=0.339	(e)	(e)	(e)	P=0.128	(e)

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Lung: Alveolar Epithelium Hyperplasia						
LESION RATES						
OVERALL (a)	1/15 (7%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)
POLY-3 RATE (b)	1/15.00	0/10.00	0/10.00	0/10.00	0/10.00	1/10.00
POLY-3 PERCENT (g)	6.7%	0%	0%	0%	0%	10%
TERMINAL (d)	1/15 (7%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)
FIRST INCIDENCE	94 (T)					94 (T)
STATISTICAL TESTS						
POLY 3	P=0.349	P=0.580N	P=0.580N	P=0.580N	P=0.580N	P=0.668
POLY 1.5	P=0.349	P=0.580N	P=0.580N	P=0.580N	P=0.580N	P=0.668
POLY 6	P=0.349	P=0.580N	P=0.580N	P=0.580N	P=0.580N	P=0.668
COCH-ARM / FISHERS	P=0.346	P=0.600N	P=0.600N	P=0.600N	P=0.600N	P=0.650
MAX-ISO-POLY-3	P=0.277	P=0.229N	P=0.229N	P=0.229N	P=0.229N	P=0.395

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Lung: Alveolus nfiltration Cellular Histiocy	te					
LESION RATES						
OVERALL (a)	3/15 (20%)	0/10 (0%)	3/10 (30%)	0/10 (0%)	3/10 (30%)	4/10 (40%)
POLY-3 RATE (b)	3/15.00	0/10.00	3/10.00	0/10.00	3/10.00	4/10.00
POLY-3 PERCENT (g)	20%	0%	30%	0%	30%	40%
TERMINAL (d)	3/15 (20%)	0/10 (0%)	3/10 (30%)	0/10 (0%)	3/10 (30%)	4/10 (40%)
FIRST INCIDENCE	94 (T)		94 (T)		94 (T)	94 (T)
STATISTICAL TESTS						
POLY 3	P=0.054	P=0.188N	P=0.463	P=0.188N	P=0.463	P=0.266
POLY 1.5	P=0.054	P=0.188N	P=0.463	P=0.188N	P=0.463	P=0.266
POLY 6	P=0.054	P=0.188N	P=0.463	P=0.188N	P=0.463	P=0.266
COCH-ARM / FISHERS	P=0.058	P=0.198N	P=0.455	P=0.198N	P=0.455	P=0.261
MAX-ISO-POLY-3	P=0.099	P=0.083N	P=0.306	P=0.083N	P=0.306	P=0.163

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

	Females								
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG			
Lung: Interstitium nflammation Granulomatou	IS								
LESION RATES									
OVERALL (a)	1/15 (7%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)			
POLY-3 RATE (b)	1/15.00	0/10.00	0/10.00	0/10.00	0/10.00	1/10.00			
POLY-3 PERCENT (g)	6.7%	0%	0%	0%	0%	10%			
TERMINAL (d)	1/15 (7%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)			
FIRST INCIDENCE	94 (T)					94 (T)			
STATISTICAL TESTS									
POLY 3	P=0.349	P=0.580N	P=0.580N	P=0.580N	P=0.580N	P=0.668			
POLY 1.5	P=0.349	P=0.580N	P=0.580N	P=0.580N	P=0.580N	P=0.668			
POLY 6	P=0.349	P=0.580N	P=0.580N	P=0.580N	P=0.580N	P=0.668			
COCH-ARM / FISHERS	P=0.346	P=0.600N	P=0.600N	P=0.600N	P=0.600N	P=0.650			
MAX-ISO-POLY-3	P=0.277	P=0.229N	P=0.229N	P=0.229N	P=0.229N	P=0.395			

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Lymph Node, Mesenteric Atrophy						
LESION RATES						
OVERALL (a)	1/15 (7%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/1 (0%)	0/10 (0%)
POLY-3 RATE (b)	1/15.00	0/0.00	0/0.00	0/0.00	0/1.00	0/10.00
POLY-3 PERCENT (g)	6.7%	0%	0%	0%	0%	0%
TERMINAL (d)	1/15 (7%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/1 (0%)	0/10 (0%)
FIRST INCIDENCE	94 (T)					
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	P=0.960N	P=0.580N
POLY 1.5	(e)	(e)	(e)	(e)	P=0.960N	P=0.580N
POLY 6	(e)	(e)	(e)	(e)	P=0.960N	P=0.580N
COCH-ARM / FISHERS	P=0.372N	(e)	(e)	(e)	P=0.937N	P=0.600N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	P=0.427N	P=0.229N

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Lymph Node, Mesenteric Infiltration Cellular Histiocy	te					
LESION RATES						
OVERALL (a)	6/15 (40%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/1 (100%)	7/10 (70%)
POLY-3 RATE (b)	6/15.00	0/0.00	0/0.00	0/0.00	1/1.00	7/10.00
POLY-3 PERCENT (g)	40%	0%	0%	0%	100%	70%
TERMINAL (d)	6/15 (40%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/1 (100%)	7/10 (70%)
FIRST INCIDENCE	94 (T)				94 (T)	94 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	P=0.449	P=0.143
POLY 1.5	(e)	(e)	(e)	(e)	P=0.449	P=0.143
POLY 6	(e)	(e)	(e)	(e)	P=0.449	P=0.143
COCH-ARM / FISHERS	P=0.096	(e)	(e)	(e)	P=0.438	P=0.144
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	P=0.200	P=0.089

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Mesentery: Fat Necrosis						
LESION RATES						
OVERALL (a)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/1 (100%)
POLY-3 RATE (b)	0/0.00	0/0.00	0/0.00	0/0.00	0/0.00	1/1.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	100%
TERMINAL (d)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/1 (100%)
FIRST INCIDENCE						94 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Nose: Nerve Inflammation Chronic						
LESION RATES						
OVERALL (a)	0/15 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
POLY-3 RATE (b)	0/15.00	0/0.00	0/0.00	0/0.00	0/0.00	1/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	10%
TERMINAL (d)	0/15 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
FIRST INCIDENCE						94 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.418
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.418
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.418
COCH-ARM / FISHERS	P=0.233	(e)	(e)	(e)	(e)	P=0.400
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.128

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Nose: Respiratory Epitheliu nflammation	m					
LESION RATES						
OVERALL (a)	0/15 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
POLY-3 RATE (b)	0/15.00	0/0.00	0/0.00	0/0.00	0/0.00	1/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	10%
TERMINAL (d)	0/15 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
FIRST INCIDENCE						94 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.418
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.418
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.418
COCH-ARM / FISHERS	P=0.233	(e)	(e)	(e)	(e)	P=0.400
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.128

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Ovary: Periovarian Tissue Cyst						
LESION RATES						
OVERALL (a)	1/15 (7%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	0/10 (0%)	0/10 (0%)
POLY-3 RATE (b)	1/15.00	0/10.00	0/10.00	1/10.00	0/10.00	0/10.00
POLY-3 PERCENT (g)	6.7%	0%	0%	10%	0%	0%
TERMINAL (d)	1/15 (7%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	0/10 (0%)	0/10 (0%)
FIRST INCIDENCE	94 (T)			94 (T)		
STATISTICAL TESTS						
POLY 3	P=0.456N	P=0.580N	P=0.580N	P=0.668	P=0.580N	P=0.580N
POLY 1.5	P=0.456N	P=0.580N	P=0.580N	P=0.668	P=0.580N	P=0.580N
POLY 6	P=0.456N	P=0.580N	P=0.580N	P=0.668	P=0.580N	P=0.580N
COCH-ARM / FISHERS	P=0.455N	P=0.600N	P=0.600N	P=0.650	P=0.600N	P=0.600N
MAX-ISO-POLY-3	P=0.369N	P=0.229N	P=0.229N	P=0.395	P=0.229N	P=0.229N

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Pancreas Infiltration Cellular Mononu	clear Cell					
LESION RATES						
OVERALL (a)	7/15 (47%)	5/10 (50%)	0/10 (0%)	5/10 (50%)	4/10 (40%)	5/10 (50%)
POLY-3 RATE (b)	7/15.00	5/10.00	0/10.00	5/10.00	4/10.00	5/10.00
POLY-3 PERCENT (g)	46.7%	50%	0%	50%	40%	50%
TERMINAL (d)	7/15 (47%)	5/10 (50%)	0/10 (0%)	5/10 (50%)	4/10 (40%)	5/10 (50%)
FIRST INCIDENCE	94 (T)	94 (T)		94 (T)	94 (T)	94 (T)
STATISTICAL TESTS						
POLY 3	P=0.279	P=0.593	P=0.010N**	P=0.593	P=0.532N	P=0.593
POLY 1.5	P=0.279	P=0.593	P=0.010N**	P=0.593	P=0.532N	P=0.593
POLY 6	P=0.279	P=0.593	P=0.010N**	P=0.593	P=0.532N	P=0.593
COCH-ARM / FISHERS	P=0.282	P=0.596	P=0.013N*	P=0.596	P=0.534N	P=0.596
MAX-ISO-POLY-3	P=0.430	P=0.442	P=0.005N**	P=0.442	P=0.386N	P=0.442

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Pancreas: Acinus Atrophy Focal						
LESION RATES						
OVERALL (a)	0/15 (0%)	2/10 (20%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/15.00	2/10.00	0/10.00	0/10.00	0/10.00	0/10.00
POLY-3 PERCENT (g)	0%	20%	0%	0%	0%	0%
TERMINAL (d)	0/15 (0%)	2/10 (20%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
FIRST INCIDENCE		94 (T)				
STATISTICAL TESTS						
POLY 3	P=0.265N	P=0.139	(e)	(e)	(e)	(e)
POLY 1.5	P=0.265N	P=0.139	(e)	(e)	(e)	(e)
POLY 6	P=0.265N	P=0.139	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.274N	P=0.150	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.256N	P=0.045*	(e)	(e)	(e)	(e)

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Spleen Hematopoietic Cell Prolifera	ition					
LESION RATES						
OVERALL (a)	0/15 (0%)	1/10 (10%)	2/10 (20%)	1/10 (10%)	1/10 (10%)	1/10 (10%)
POLY-3 RATE (b)	0/15.00	1/10.00	2/10.00	1/10.00	1/10.00	1/10.00
POLY-3 PERCENT (g)	0%	10%	20%	10%	10%	10%
TERMINAL (d)	0/15 (0%)	1/10 (10%)	2/10 (20%)	1/10 (10%)	1/10 (10%)	1/10 (10%)
FIRST INCIDENCE		94 (T)				
STATISTICAL TESTS						
POLY 3	P=0.529	P=0.418	P=0.139	P=0.418	P=0.418	P=0.418
POLY 1.5	P=0.529	P=0.418	P=0.139	P=0.418	P=0.418	P=0.418
POLY 6	P=0.529	P=0.418	P=0.139	P=0.418	P=0.418	P=0.418
COCH-ARM / FISHERS	P=0.530	P=0.400	P=0.150	P=0.400	P=0.400	P=0.400
MAX-ISO-POLY-3	P=0.321	P=0.128	P=0.045*	P=0.128	P=0.128	P=0.128

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Spleen Pigmentation Hemosiderin						
LESION RATES						
OVERALL (a)	15/15 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	15/15.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	100%	100%	100%	100%	100%	100%
TERMINAL (d)	15/15 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	94 (T)					
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Spleen: Capsule Inflammation Chronic						
LESION RATES						
OVERALL (a)	0/15 (0%)	0/10 (0%)	1/10 (10%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/15.00	0/10.00	1/10.00	0/10.00	0/10.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	10%	0%	0%	0%
TERMINAL (d)	0/15 (0%)	0/10 (0%)	1/10 (10%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
FIRST INCIDENCE			94 (T)			
STATISTICAL TESTS						
POLY 3	P=0.525N	(e)	P=0.418	(e)	(e)	(e)
POLY 1.5	P=0.525N	(e)	P=0.418	(e)	(e)	(e)
POLY 6	P=0.525N	(e)	P=0.418	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.525N	(e)	P=0.400	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.552N	(e)	P=0.128	(e)	(e)	(e)

PCN 66/67 comparison study CAS Number: PCNCOMPARISN Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Stomach, Forestomach Infiltration Cellular Mononue	clear Cell					
LESION RATES						
OVERALL (a)	1/15 (7%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
POLY-3 RATE (b)	1/15.00	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00
POLY-3 PERCENT (g)	6.7%	0%	0%	0%	0%	0%
TERMINAL (d)	1/15 (7%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
FIRST INCIDENCE	94 (T)					
STATISTICAL TESTS						
POLY 3	P=0.469N	P=0.580N	P=0.580N	P=0.580N	P=0.580N	P=0.580N
POLY 1.5	P=0.469N	P=0.580N	P=0.580N	P=0.580N	P=0.580N	P=0.580N
POLY 6	P=0.469N	P=0.580N	P=0.580N	P=0.580N	P=0.580N	P=0.580N
COCH-ARM / FISHERS	P=0.469N	P=0.600N	P=0.600N	P=0.600N	P=0.600N	P=0.600N
MAX-ISO-POLY-3	P=0.218N	P=0.229N	P=0.229N	P=0.229N	P=0.229N	P=0.229N

PCN 66/67 comparison study CAS Number: PCNCOMPARISN Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Stomach, Glandular Infiltration Cellular Mononu	clear Cell					
LESION RATES						
OVERALL (a)	4/15 (27%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	3/10 (30%)
POLY-3 RATE (b)	4/15.00	0/0.00	0/0.00	0/0.00	0/0.00	3/10.00
POLY-3 PERCENT (g)	26.7%	0%	0%	0%	0%	30%
TERMINAL (d)	4/15 (27%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	3/10 (30%)
FIRST INCIDENCE	94 (T)					94 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.603
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.603
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.603
COCH-ARM / FISHERS	P=0.518	(e)	(e)	(e)	(e)	P=0.601
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.436

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

			Females			
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG
Thymus Atrophy						
LESION RATES						
OVERALL (a)	0/15 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	5/10 (50%)	9/10 (90%)
POLY-3 RATE (b)	0/15.00	0/10.00	0/10.00	1/10.00	5/10.00	9/10.00
POLY-3 PERCENT (g)	0%	0%	0%	10%	50%	90%
TERMINAL (d)	0/15 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	5/10 (50%)	9/10 (90%)
FIRST INCIDENCE				94 (T)	94 (T)	94 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	(e)	P=0.418	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	(e)	(e)	P=0.418	P<0.001**	P<0.001**
POLY 6	P<0.001**	(e)	(e)	P=0.418	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	P=0.400	P=0.005**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	P=0.128	P<0.001**	P<0.001**

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

Females							
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG	
Thyroid Gland Cyst							
LESION RATES							
OVERALL (a)	0/15 (0%)	1/10 (10%)	0/10 (0%)	3/10 (30%)	0/10 (0%)	1/10 (10%)	
POLY-3 RATE (b)	0/15.00	1/10.00	0/10.00	3/10.00	0/10.00	1/10.00	
POLY-3 PERCENT (g)	0%	10%	0%	30%	0%	10%	
TERMINAL (d)	0/15 (0%)	1/10 (10%)	0/10 (0%)	3/10 (30%)	0/10 (0%)	1/10 (10%)	
FIRST INCIDENCE		94 (T)		94 (T)		94 (T)	
STATISTICAL TESTS							
POLY 3	P=0.437	P=0.418	(e)	P=0.040*	(e)	P=0.418	
POLY 1.5	P=0.437	P=0.418	(e)	P=0.040*	(e)	P=0.418	
POLY 6	P=0.437	P=0.418	(e)	P=0.040*	(e)	P=0.418	
COCH-ARM / FISHERS	P=0.439	P=0.400	(e)	P=0.052	(e)	P=0.400	
MAX-ISO-POLY-3	P=0.228	P=0.128	(e)	P=0.013*	(e)	P=0.128	

PCN 66/67 comparison study CAS Number: PCNCOMPARISN

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

Females							
DOSE	0 NG/KG	1 NG/KG	10 NG/KG	50 NG/KG	100 NG/KG	200 NG/KG	
Urinary Bladder Infiltration Cellular Lympho	cyte						
LESION RATES							
OVERALL (a)	1/15 (7%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)	
POLY-3 RATE (b)	1/15.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00	
POLY-3 PERCENT (g)	6.7%	0%	0%	0%	0%	0%	
TERMINAL (d)	1/15 (7%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)	
FIRST INCIDENCE	94 (T)						
STATISTICAL TESTS							
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.580N	
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.580N	
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.580N	
COCH-ARM / FISHERS	P=0.377N	(e)	(e)	(e)	(e)	P=0.600N	
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.229N	

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

PCN 66/67 comparison study CAS Number: PCNCOMPARISN

Date Report Requested: 08/27/2015 Time Report Requested: 10:28:05 First Dose M/F: NA / 10/13/03 Lab: BAT

LEGEND

(a)	Number of tumor-bearing animals/number of animals examined at site.
(b)	Number of tumor-bearing animals/Poly-3 number
(d)	Observed incidence at terminal kill.
(e)	Value of statistic cannot be computed.
(f)	Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group.
(g)	Poly-3 adjusted lifetime tumor incidence.
(n)	No statistics are calculated if all dose groups have fewer than two tumors.
(I)	Interim sacrifice
(T)	Terminal sacrifice
#	Tumor rates based on numbers of animals necropsied.
*	To the right of any statistical result, indicates significance at (P<=0.05).
**	To the right of any statistical result, indicates significance at (P<=0.01).
Ν	Indicates a negative trend for all tests
	The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.
	*** END OF REPORT ***